{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Adénocarcinome bronchioloalvéolaire : Questions médicales les plus fréquentes",
"headline": "Adénocarcinome bronchioloalvéolaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Adénocarcinome bronchioloalvéolaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-28",
"dateModified": "2024-10-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Adénocarcinome bronchioloalvéolaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Adénocarcinome pulmonaire",
"url": "https://recherchemedicale.com/mesh/D000077192",
"about": {
"@type": "MedicalCondition",
"name": "Adénocarcinome pulmonaire",
"code": {
"@type": "MedicalCode",
"code": "D000077192",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.894.797.520.055"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Adénocarcinome bronchioloalvéolaire",
"alternateName": "Adenocarcinoma, Bronchiolo-Alveolar",
"code": {
"@type": "MedicalCode",
"code": "D002282",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Cormac McCarthy",
"url": "https://recherchemedicale.com/author/Cormac%20McCarthy",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, St. Vincent's University Hospital and University College Dublin, Dublin, Ireland."
}
},
{
"@type": "Person",
"name": "Bashiru Ibrahim",
"url": "https://recherchemedicale.com/author/Bashiru%20Ibrahim",
"affiliation": {
"@type": "Organization",
"name": "Nanomedicine, Drug Delivery & Nanotoxicology (NDDN) Lab, School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K."
}
},
{
"@type": "Person",
"name": "Taiwo Hassan Akere",
"url": "https://recherchemedicale.com/author/Taiwo%20Hassan%20Akere",
"affiliation": {
"@type": "Organization",
"name": "Nanomedicine, Drug Delivery & Nanotoxicology (NDDN) Lab, School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K."
}
},
{
"@type": "Person",
"name": "Swaroop Chakraborty",
"url": "https://recherchemedicale.com/author/Swaroop%20Chakraborty",
"affiliation": {
"@type": "Organization",
"name": "School of Geography, Earth and Environmental Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, U.K."
}
},
{
"@type": "Person",
"name": "Eugenia Valsami-Jones",
"url": "https://recherchemedicale.com/author/Eugenia%20Valsami-Jones",
"affiliation": {
"@type": "Organization",
"name": "School of Geography, Earth and Environmental Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, U.K."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma.",
"datePublished": "2023-10-01",
"url": "https://recherchemedicale.com/article/37808711",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2023.09.29.560194"
}
},
{
"@type": "ScholarlyArticle",
"name": "Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma.",
"datePublished": "2023-11-07",
"url": "https://recherchemedicale.com/article/37931288",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1158/2159-8290.CD-23-0289"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinicopathologic Features and Frozen Diagnostic Pitfalls of Bronchiolar Adenoma/Ciliated Muconodular Papillary Tumors (BA/CMPTs).",
"datePublished": "2023-02-07",
"url": "https://recherchemedicale.com/article/36764678",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PAS.0000000000002016"
}
},
{
"@type": "ScholarlyArticle",
"name": "Viral Bronchiolo-Alveolitis From Coronavirus OC43 and Rhinovirus-Simulating SARS-CoV-2 Infection.",
"datePublished": "2022-08-17",
"url": "https://recherchemedicale.com/article/36127976",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.28093"
}
},
{
"@type": "ScholarlyArticle",
"name": "Progressive changes in the protein expression profile of alveolar septa in early-stage lung adenocarcinoma.",
"datePublished": "2024-04-11",
"url": "https://recherchemedicale.com/article/38600426",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10147-024-02507-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://recherchemedicale.com/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par siège",
"item": "https://recherchemedicale.com/mesh/D009371"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du thorax",
"item": "https://recherchemedicale.com/mesh/D013899"
},
{
"@type": "ListItem",
"position": 5,
"name": "Adénocarcinome pulmonaire",
"item": "https://recherchemedicale.com/mesh/D000077192"
},
{
"@type": "ListItem",
"position": 6,
"name": "Adénocarcinome bronchioloalvéolaire",
"item": "https://recherchemedicale.com/mesh/D002282"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Adénocarcinome bronchioloalvéolaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Adénocarcinome bronchioloalvéolaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-01-22",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Adénocarcinome bronchioloalvéolaire",
"description": "Comment diagnostiquer l'adénocarcinome bronchioloalvéolaire ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nQuels signes radiologiques indiquent ce cancer ?\nQuel rôle joue la PET scan dans le diagnostic ?\nPeut-on détecter ce cancer par des analyses sanguines ?",
"url": "https://recherchemedicale.com/mesh/D002282#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Adénocarcinome bronchioloalvéolaire",
"description": "Quels sont les symptômes courants de ce cancer ?\nComment se manifeste l'essoufflement dans ce cancer ?\nY a-t-il des symptômes systémiques associés ?\nLes symptômes varient-ils selon le stade du cancer ?\nPeut-on avoir des symptômes sans avoir de tumeur visible ?",
"url": "https://recherchemedicale.com/mesh/D002282#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Adénocarcinome bronchioloalvéolaire",
"description": "Comment prévenir l'adénocarcinome bronchioloalvéolaire ?\nLe dépistage précoce est-il utile ?\nQuels facteurs environnementaux influencent le risque ?\nLe mode de vie joue-t-il un rôle dans la prévention ?\nLes antécédents familiaux influencent-ils le risque ?",
"url": "https://recherchemedicale.com/mesh/D002282#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Adénocarcinome bronchioloalvéolaire",
"description": "Quels traitements sont disponibles pour ce cancer ?\nLa chirurgie est-elle toujours une option ?\nQuel est le rôle de la chimiothérapie ?\nLa radiothérapie est-elle efficace pour ce type de cancer ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://recherchemedicale.com/mesh/D002282#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Adénocarcinome bronchioloalvéolaire",
"description": "Quelles complications peuvent survenir avec ce cancer ?\nComment la métastase affecte-t-elle le pronostic ?\nL'insuffisance respiratoire est-elle fréquente ?\nLes infections sont-elles un risque pour ces patients ?\nQuelles sont les complications liées au traitement ?",
"url": "https://recherchemedicale.com/mesh/D002282#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Adénocarcinome bronchioloalvéolaire",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de ce cancer ?\nLes antécédents médicaux jouent-ils un rôle ?\nLes facteurs génétiques sont-ils importants ?\nL'exposition professionnelle peut-elle augmenter le risque ?",
"url": "https://recherchemedicale.com/mesh/D002282#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'adénocarcinome bronchioloalvéolaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (CT) et biopsie pulmonaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la bronchoscopie et l'analyse histologique des tissus."
}
},
{
"@type": "Question",
"name": "Quels signes radiologiques indiquent ce cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des opacités en verre dépoli et des nodules peuvent être observés sur les images."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la PET scan dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La PET scan aide à évaluer l'activité métabolique des lésions suspectes."
}
},
{
"@type": "Question",
"name": "Peut-on détecter ce cancer par des analyses sanguines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analyses sanguines ne sont pas spécifiques, mais peuvent aider à évaluer la santé générale."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de ce cancer ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la toux persistante, l'essoufflement et la douleur thoracique."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'essoufflement dans ce cancer ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'essoufflement peut survenir même au repos, en raison de l'obstruction des voies respiratoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la perte de poids et la fatigue peuvent également apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le stade du cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver avec l'avancement de la maladie."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans avoir de tumeur visible ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent apparaître même si la tumeur est petite ou non détectable."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'adénocarcinome bronchioloalvéolaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et l'exposition à des agents cancérigènes peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il utile ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage peut aider à détecter le cancer à un stade précoce, améliorant les chances de traitement."
}
},
{
"@type": "Question",
"name": "Quels facteurs environnementaux influencent le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition à la pollution de l'air et aux produits chimiques industriels augmente le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain, incluant une alimentation équilibrée, peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer du poumon peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour ce cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent envisagée si le cancer est localisé et opérable."
}
},
{
"@type": "Question",
"name": "Quel est le rôle de la chimiothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est utilisée pour réduire la taille des tumeurs et prévenir les récidives."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace pour ce type de cancer ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être efficace, surtout pour les cas avancés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés peuvent être proposés selon les caractéristiques génétiques de la tumeur."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ce cancer ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la métastase, l'insuffisance respiratoire et les infections."
}
},
{
"@type": "Question",
"name": "Comment la métastase affecte-t-elle le pronostic ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La métastase réduit généralement le pronostic et complique le traitement."
}
},
{
"@type": "Question",
"name": "L'insuffisance respiratoire est-elle fréquente ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'insuffisance respiratoire est une complication courante dans les stades avancés."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles un risque pour ces patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison de l'immunosuppression."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications liées au traitement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent entraîner des effets secondaires comme la fatigue, les nausées et l'anémie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'exposition à l'amiante et la pollution de l'air sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de ce cancer ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 50 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies pulmonaires augmentent le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques sont-ils importants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques peuvent prédisposer certains individus à ce cancer."
}
},
{
"@type": "Question",
"name": "L'exposition professionnelle peut-elle augmenter le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des professions exposant à des substances cancérigènes augmentent le risque."
}
}
]
}
]
}
Nanomedicine, Drug Delivery & Nanotoxicology (NDDN) Lab, School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
School of Geography, Earth and Environmental Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
Publications dans "Adénocarcinome bronchioloalvéolaire" :
Nanomedicine, Drug Delivery & Nanotoxicology (NDDN) Lab, School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
School of Geography, Earth and Environmental Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
Publications dans "Adénocarcinome bronchioloalvéolaire" :
Nanomedicine, Drug Delivery & Nanotoxicology (NDDN) Lab, School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
Publications dans "Adénocarcinome bronchioloalvéolaire" :
Lung adenocarcinoma (LUAD), commonly driven by...
Treatment resistance limits response to KRAS inhibitors in LUAD patients. We find LUAD residual disease following KRAS targeting is composed of AT1-like cancer cells with the capacity to reignite tumo...
Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7% of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in LUAD, but clinical ben...
To describe the histologic features of bronchiolar adenoma/ciliated muconodular papillary tumors (BA/CMPTs) and analyze the pitfalls in diagnosis from frozen sections. A total of 208 frozen and perman...
Viruses are the most common cause of acute lower respiratory tract. The respiratory syncytial virus infection is most commonly associated with viral bronchiolitis. Rhinovirus and coronavirus OC43 are ...
Adenocarcinomas show a stepwise progression from atypical adenomatous hyperplasia (AAH) through adenocarcinoma in situ (AIS) to invasive adenocarcinoma (IA). Immunoglobulin superfamily containing leuc...
We investigated the changes in protein expression during adenocarcinoma progression in the pre-existing alveolar septa by assessing ISLR, αSMA, and FAP expression in normal lung, AAH, AIS, and IA. Fou...
Normal alveolar septa expressed ISLR. The ISLR level in the alveolar septa decreased in AAH and AIS tissues when compared with that in normal lung tissue. The αSMA-positive area gradually increased fr...
FAP-positive fibroblasts may contribute to tumor stroma formation in early-stage lung adenocarcinoma, and this could influence the development of therapeutic strategies targeting FAP-positive CAFs for...
Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer and presents clinically with a high degree of biological heterogeneity and distinct clinical outcomes. The current paradigm of L...
This study aims to investigate the correlations between alveolar collapse, tumor size, and tumor infiltrating lymphocytes (TILs), while also evaluating the prognostic significance of alveolar collapse...
Intratumoral macrophages are reportedly involved in tumor progression in non-small cell lung cancer; however, little is known about the prognostic impact and function of alveolar macrophages (AMs). Th...
We investigated 514 patients with pathological stage I lung adenocarcinoma who underwent complete resection with lobectomy or pneumonectomy. The numbers of peri-tumoral AMs were counted, and patients ...
The median number of peri-tumoral AMs per alveolar space was 15.5. Patients with a high peri-tumoral AM content had significantly shorter disease-free survival and overall survival than patients with ...
The number of peri-tumoral AMs had a strong impact on disease-free survival in patients with stage I lung adenocarcinoma....
The prognostic significance and role of extratumoral alveolar macrophages (exAMs) in lung adenocarcinoma (LUAD) patients remain unknown. In this study, we investigated the prognostic impact and gene e...
The limited efficacy of currently approved immunotherapies in EGFR-driven lung adenocarcinoma (LUAD) underscores the need to better understand alternative mechanisms governing local immunosuppression ...